Exploiting membrane vesicles (MVs) derived from avian pathogenic Escherichia coli as a cross-protective subunit vaccine candidate against avian colibacillosis

Quick Facts

• Publication title: Exploiting membrane vesicles (MVs) derived from avian pathogenic Escherichia coli as a cross-protective subunit vaccine candidate against avian colibacillosis
• Journal: POULTRY SCI
• Year: 2024
• DOI: 10.1016/j.psj.2024.104148
• PMID/PMCID: 39142031; PMC11379662

Research overview

Here, we evaluated the immunoprotective efficacy of MVs derived from the LPS low-expressed APEC strain FY26ΔmsbB, which was an APEC mutant strain with a deletion of the msbB gene. These findings suggest that MVs generated from the LPS low-expressed APEC strain FY26ΔmsbB represent a novel and empirically validated subunit vaccine for the prevention and control of infections by various APEC serotypes.

Key findings

Avian pathogenic Escherichia coli (APEC) is a notable pathogen that frequently leads to avian colibacillosis, posing a substantial risk to both the poultry industry and public health.

The commercial vaccines against avian colibacillosis are primarily inactivated vaccines, but their effectiveness is limited to specific serotypes.

Recent advances have highlighted bacterial membrane vesicles (MV) as a promising candidate in vaccine research.

How to produce bacterial MVs vaccines on a large scale is a significant challenge for the industrialization of MVs.

Echo Biotech Role

Echo Biotech contributed EV characterization.

Related platforms: Exoomics®

Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)

References

Original publication: Exploiting membrane vesicles (MVs) derived from avian pathogenic Escherichia coli as a cross-protective subunit vaccine candidate against avian colibacillosis Poultry Science. 2024. DOI: 10.1016/j.psj.2024.104148. PMID/PMCID: 39142031; PMC11379662.